2026-10-25
Stryker clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,990 +1.35%
S&P 7,377 +0.31%
GOLD $4,075 −0.94%
BTC $75,677 −0.09%
VIX 25.64 −9.01%
latest tape · as of 20:08 UTC
The Screen · Healthcare · Medical Devices
Stryker Corporation
SYK · a US exchange · USD · Market cap $119.6B · 56,000 employees
Stryker Corporation operates as a medical technology company in the United States and internationally.
Not yet scored325.87 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price325.87 USD at the 6 Nov 2026 close
- Our value readFair vs our fair value, as of 6 Nov 2026
- Our regime readMarkup, as of 7 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.13)
- Last reviewed6 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $274.74 to $457.91, base estimate $363.16 (screen dated 2026-11-06).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning political selling, disclosed 2026-09-25
- Options put/call open interest 0.13, read 2026-11-05
- Ethical screen not yet scored
Price325.87 USD
Fair value363.16
Ethical score83.2/100
Value readFairas of 6 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup272.36+19.6% to today ✓Distribution gives way to Markup after a 17% slide in 6 weeks
2026-08-30Read Distribution327.70-0.6% to today ✓Markup gives way to Distribution first Distribution read since July
2026-07-30Read Markup330.25-1.3% to today Distribution gives way to Markup after an 8% rise in 4 weeks
2026-07-02Read Distribution305.66+6.6% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Stryker Corporation holds its Markup at $325.87. The statistical read favours the sellers, held for 1 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 1 days |
| Price at the screen | $325.87 |
| Valuation | 32.31 trailing · 18.72 forward price to earnings |
| Values screen | Not scored · score 83.2 |
| Beta | 0.78 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 33.15% | Below 33% | Interest-bearing debt is just 33.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.19% | Below 33% | Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit. | Pass |
| Receivables | 16.83% | Below 49% | Money owed to the company is 16.8% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Stryker clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Stryker clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 33%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 6 Nov 2026: it trades at roughly an 8% discount to our $363.16 fair value, moderate competitive moat, 9.40% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 10.3% discount to the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +10% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere our models see it going: fair-value estimate $363.16, with a range of $274.74 to $457.91, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a moderate moat. It trades close to our $363.16 fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | 18.7xpriced for continued growth |
| Trailing P/E | 32.3xa premium valuation |
| EPS, trailing | 9.65 |
| EPS, forward | 16.65 |
| Revenue growth | +9.4%steady growth |
| Profit margin | 14.4%thin but positive margins |
| Return on equity | 16.5%a solid return on shareholder capital |
| FCF yield | 3.44% |
| Dividend yield | 1.15% |
| Debt to equity | 0.64moderate, manageable leverage |
| Current ratio | 2.16comfortably covers its short-term bills |
| Beta | 0.78steadier than the market |
| Short interest, float | 0.02% |
| 52-week range | 267.00 - 389.33 |
| Moat | MODERATE |
| Market cap | $119.6B |
| Employees | 56,000 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSYK trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Markup $339.65
+10.6% Entry 23
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389.
2026-10-29
Markup $307.15
+4.7% Entry 22
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Markup $293.23
+0.0% Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27
Markup $293.23
+0.0% Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26
Markup $293.23
+0.0% Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Markup $293.23
+0.0% Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24
Markup $293.23
+0.0% Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23
Markup $293.23
+0.0% Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Markup $293.23
+0.0% Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18
Markup $293.23
+7.7% Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 7.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Stryker (SYK) Stock May Be 22% Undervalued On Manufacturing Issues Yahoo Finance · 2d ago
- What 3.4% GDP Growth and a 4.2% Jobless Rate Say About a Hard Day on Wall Street Yahoo Finance · 2d ago
- Should You Buy Intuitive Surgical Stock Now Or Wait? Yahoo Finance · 2d ago
- Zimmer raises sales forecast despite slower knee business Yahoo Finance · 3d ago
- Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy Yahoo Finance · 3d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
MDTMedtronic
ABTAbbott Laboratories
BSXBoston Scientific
EWEdwards Lifesciences
DXCMDexcom
GEHCGE HealthCare
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-11 | FINK MARY KATHRYN | Officer | 8,720 | $2,473,756 | |
| 2026-05-08 | FINK MARY KATHRYN | Officer | 21,582 | $3,625,388 | |
| 2026-05-06 | MACEDA EMMANUEL PEREZ | Director | 762 | · | |
| 2026-05-06 | KING DEBRA | Chief Technology Officer | 1,016 | · | |
| 2026-05-06 | SKEETE TATUM LISA M | Director | 762 | · | |
| 2026-05-06 | CAFORIO GIOVANNI | Director | 762 | · | |
| 2026-05-06 | RUGGERI RACHEL | Director | 762 | · | |
| 2026-05-06 | MONTAGNINO KIMBERLY ANN | Officer | 677 | · | |
| 2026-05-06 | STRYKER RONDA E | Director | 762 | · | |
| 2026-05-06 | SILVERNAIL ANDREW K. | Director | 762 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-25 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 15K–50K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 15K–50K |
| 2026-09-11 | Ro Khanna | Democrat | sell | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $282.58 | +9.3% | · | $1,093 | +9.3% |
| 2 months | $339.15 | -8.9% | · | $911 | -8.9% |
| 3 months | $336.30 | -8.2% | $0.88 | $921 | -7.9% |
| 6 months | $351.14 | -12.1% | $1.76 | $885 | -11.5% |
| 1 year | $381.37 | -19.0% | $3.44 | $819 | -18.1% |
| 2 years | $341.68 | -9.6% | $6.72 | $923 | -7.7% |
| 3 years | $272.59 | +13.3% | $9.82 | $1,169 | +16.9% |
| 5 years | $242.91 | +27.1% | $15.36 | $1,335 | +33.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SYK does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.